Enanta Pharmaceuticals Raises $65 Million in Upsized Public Offering to Advance RSV and Immunology Pipeline
Key Insights
Enanta Pharmaceuticals completed an upsized public offering of 6.5 million shares at $10.00 per share, raising $65 million in gross proceeds to fund its clinical programs.
The biotechnology company focuses on small molecule drug discovery for virology and immunology, with current clinical programs targeting respiratory syncytial virus (search) (RSV).
Enanta's immunology pipeline aims to develop treatments for inflammatory diseases (search) by targeting key drivers of the type 2 immune response, including KIT (search) and STAT6 inhibition.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) successfully completed an upsized underwritten public offering, raising $65 million in gross proceeds to advance its clinical-stage virology and immunology programs. The Watertown, Massachusetts-based biotechnology company priced 6.5 million shares of common stock at $10.00 per share, with the offering expected to close on October 2, 2025.
The offering was initially announced for $50 million but was increased due to investor demand. Enanta also granted underwriters a 30-day option to purchase up to an additional 975,000 shares at the public offering price, less underwriting discounts and commissions. J.P. Morgan, Jefferies and Evercore ISI served as joint book-running managers for the offering.
Clinical Pipeline Focus
Enanta is leveraging its chemistry-driven approach and drug discovery capabilities to develop small molecule drugs with an emphasis on virology and immunology indications. The company's clinical programs are currently focused on respiratory syncytial virus (search) (RSV), a significant respiratory pathogen.
The company's earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases (search) by targeting key drivers of the type 2 immune response, including KIT (search) and STAT6 inhibition. This approach represents a targeted strategy for addressing inflammatory conditions through specific molecular pathways.
Established Track Record
Enanta has demonstrated its drug discovery capabilities through the development of glecaprevir, a protease inhibitor that has become part of one of the leading treatment regimens for curing hepatitis C virus (search) (HCV) infection. The drug is commercialized by AbbVie (search) in numerous countries under the tradenames MAVYRET® in the United States and MAVIRET® internationally as part of the glecaprevir/pibrentasvir combination therapy.
A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie (search) provides ongoing funding to support the company's operations, creating a sustainable revenue stream to complement the newly raised capital.
Financial Structure
The public offering was conducted pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on November 22, 2023, and became effective on February 8, 2024. This registration framework allowed for the efficient execution of the capital raise.
The proceeds from this offering will provide Enanta with additional resources to advance its clinical programs in RSV and continue development of its immunology pipeline targeting inflammatory diseases (search) through novel mechanisms of action.